Vote Scores

Home / Companies / Amylyx Pharmaceuticals, Inc.

Company · votes reported on Form N-PXAMLX · SEC company no. 1658551

Amylyx Pharmaceuticals, Inc.

How funds and institutional managers reported voting their shares, year to 30 June 2026

Filers reporting
302year to 30 June 2026
Against management on pay
40.5%117 of 289 reporting filers
Same, by reported shares
14.5%shares reported on Form N-PX
Meetings on file
3across 3 seasons
56.3% for39.0% against4.7% other40.5% against management300 filers on say-on-pay

foragainstabstain, withhold or otheramber tick: the portion cast against management

For the year to 30 June 2026, 302 funds and managers listed Amylyx Pharmaceuticals, Inc. in their Form N-PX filings (one meeting).

On the advisory vote on executive pay, 117 of the 289 filers that reported a position voted against management (40.5%), 33.9 percentage points above the median company on this site (6.6%). By reported shares the figure is 14.5% (median 2.9%). These are shares of the filers reporting on Form N-PX, not of all votes cast at the meeting.

Among the largest fund families, 23 voted with management on pay and 17 voted against: DWS, Dimensional, Principal, Victory Capital, Nuveen and TIAA, ProShares and ProFunds, AllianceBernstein and Morgan Stanley, Eaton Vance and Calvert and others.

Meetings

Meeting dateSeasonFilers reportingItemsAgainst management on pay
4 Jun 2026year to 30 June 2026302340.5%
5 Jun 2025year to 30 June 2025129374.0%
6 Jun 2024year to 30 June 2024240412.7%

Meetings with 20 or more reporting filers have their own page with every item. Dates are as filers typed them; dates up to three days apart are treated as one meeting.

Say-on-pay: this company and the median

year to 30 June 2026Amylyx Pharmaceuticals, Inc.Median company
Reporting filers voting against management40.5%6.6%
Reported shares voted against management14.5%2.9%

Among filers reporting on Form N-PX. The median is over 3,799 companies with a say-on-pay item reported by 20 or more filers.

How the largest families voted

Meeting of 4 Jun 2026: say-on-pay and each shareholder proposal that could be told apart.

FamilySay-on-pay
VanguardFor
BlackRock and iSharesFor
FidelityFor
DimensionalAgainst *
State Street and SPDRFor
Franklin TempletonAgainst *
InvescoAgainst *
EquitableFor
Charles SchwabFor
Nuveen and TIAAAgainst *
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertAgainst *
J.P. MorganFor
Goldman SachsFor
PGIM and PrudentialFor
Jackson National fundsAgainst *
Northern Trust and FlexSharesFor
SEIFor
T. Rowe PriceAgainst *
Lincoln FinancialFor
VoyaFor
First TrustAgainst *
Russell InvestmentsFor
NationwideFor
Victory CapitalAgainst *
Brighthouse FundsAgainst
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonFor
PrincipalAgainst *
Pacific Life fundsFor
Global XFor
Federated HermesFor
AllianceBernsteinAgainst *
DWSAgainst *
MassMutualFor
Janus HendersonFor
Neuberger BermanFor
Natixis and Loomis SaylesAgainst *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

By season

SeasonFilers reportingAgainst management on pay, filersBy reported sharesSay-on-pay split
year to 30 June 202424112.7%7.6%
year to 30 June 202513074.0%52.1%
year to 30 June 202630240.5%14.5%

Category mix

Share of the vote records reported for this company, by the category filers chose.

CategoryVote recordsShare
SECTION 14A SAY-ON-PAY VOTES1,27350.6%
DIRECTOR ELECTIONS84633.6%
AUDIT-RELATED39915.8%

Questions

How did large funds vote at Amylyx Pharmaceuticals, Inc.?

For the year to 30 June 2026, 289 Form N-PX filers reported a say-on-pay vote at Amylyx Pharmaceuticals, Inc.; 117 voted against management (40.5%). The table on this page lists the position of each of the largest fund families on say-on-pay and on each shareholder proposal that could be told apart in the filings.

Were there shareholder proposals at Amylyx Pharmaceuticals, Inc.?

No proposal from security holders was reported by enough filers to be shown for the year to 30 June 2026.

Is this the meeting result?

No. The figures are shares of the funds and managers that file Form N-PX, and of the shares they reported. Holders that do not file the form (individuals, most foreign investors, insiders) are not included, so the split here can differ widely from the certified result, which Amylyx Pharmaceuticals, Inc. reports on Form 8-K.

Where does the data come from?

From Form N-PX filings on the SEC's EDGAR system, grouped by company. Filers type company names and meeting dates themselves; this site groups spellings of the same company and folds meeting dates up to three days apart. Data runs through 23 Sep 2026; the median compares 3,799 companies.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Amylyx Pharmaceuticals, Inc., grouped by company. The name is the most common spelling among filers; the ticker and SEC company number come from the SEC company tickers file, matched on the exact name. Not verified by the SEC. Filings read through 23 Sep 2026; page built 26 Sep 2026.